Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 9/20 | 0.68 |
| ▸ | CIT | O14578 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.43 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.43 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.43 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13258393 | 0.86 | GPR142 (0.60) | GPR142 | |
| SCHEMBL2684311 | 0.81 | GPR142 (1.00) | GPR142 | |
| SCHEMBL2683696 | 0.81 | GPR142 (0.57) | GPR142 | |
| SCHEMBL2683081 | 0.78 | GPR142 (0.66) | GPR142 | |
| SCHEMBL2685523 | 0.78 | GPR142 (0.56) | GPR142 | |
| SCHEMBL2684777 | 0.77 | GPR142 (0.57) | GPR142 | |
| SCHEMBL2684305 | 0.77 | GPR142 (0.66) | GPR142CITSMN1; SMN2MAPT | |
| SCHEMBL2685347 | 0.76 | GPR142 (0.55) | GPR142SMN1; SMN2 | |
| SCHEMBL2685337 | 0.74 | GPR142 (0.52) | GPR142MMP2 | |
| SCHEMBL2684698 | 0.74 | GPR142 (0.61) | GPR142CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785468-B2 | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | AMGEN INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | IAPP, INSR, AMY2A | GPR142 2779/4885CIT 3081/4885MMP2 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.